$WGS News

GeneDx: The 50% Crash Creates A Compelling Entry

Why Is GeneDx Stock Surging Thursday?

GeneDx Holdings Corp. 2026 Q1 - Results - Earnings Call Presentation

Canaccord Genuity Maintains Buy on GeneDx Holdings, Lowers Price Target to $75

Wells Fargo Maintains Overweight on GeneDx Holdings, Lowers Price Target to $75

Guggenheim Maintains Buy on GeneDx Holdings, Lowers Price Target to $70

BTIG Maintains Buy on GeneDx Holdings, Lowers Price Target to $90

GeneDx Holdings Corp (NASDAQ:WGS) Plunges 44% After Disastrous Q1 2026 Miss

CORRECTION: GeneDx Hldgs Q1 Adj. EPS $(0.28) Misses $(0.01) Estimate, Sales $102.300M Miss $112.956M Estimate

GeneDx Holdings Lowers FY2026 Sales Guidance from $540.000M-$555.000M to $475.000M-$490.000M vs $550.216M Est

Guggenheim Maintains Buy on GeneDx Holdings, Lowers Price Target to $100

Assessing GeneDx Holdings (WGS) Valuation After Recent Share Price Weakness

GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know

Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target

Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage?

GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPC

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge?

Is GeneDx Holdings (WGS) Pricing In Its Sharp 27% Weekly Share Price Move?

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C